We are international

Sydney 2005: Targeting of VEGF and PDGF Signaling by Receptor Tyrosine Kinase Inhibitors Impairs...
By Ivan Van Riet, MD

Dr. Van Riet discussed the molecules that could control disease development, specifically discussing VEGF and PDGF signaling by receptor tyrosine kinase inhibitors (RTKI). In a model system, Dr. Van Riet showed the ability of MM cells to stimulate angiogenesis and increase microvessel density (MVD). RTKI impaired myeloma cell-mediated blood vessel formation in an in vitro system. Using an in vivo mouse model, administration of RTIs resulted in a significant reduction in MVD. These data suggest that RTKIs may be able to inhibit microvessel formation.

Back to session summary

 related articles